Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 8/20 | 0.54 |
| ▸ | EDNRB | P24530 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229949 | 1.00 | EDNRA (0.54) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL6065374 | 1.00 | EDNRA (0.54) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL6065513 | 1.00 | EDNRA (0.54) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL3229958 | 1.00 | EDNRA (0.54) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL24179855 | 0.80 | MEN1 (0.49) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL18575422 | 0.76 | ALDH1A1 (0.45) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL7852876 | 0.75 | EDNRA (0.71) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL11483539 | 0.75 | EDNRA (0.71) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL28435319 | 0.73 | EDNRA (0.56) | EDNRAEDNRBMEN1KMT2APOLB | |
| SCHEMBL6818186 | 0.70 | EDNRA (1.00) | EDNRAEDNRBMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745462-B2 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2010-06-29 | — | — | US | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | EDNRA 291/4885EDNRB 257/4885MEN1 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.